Date: 2014-07-08
Type of information: Collaboration agreement
Compound: drug discovery programmes
Company: Evotec (Germany) Fraunhofer Institute for Molecular Biology and Applied Ecology IME (Germany)
Therapeutic area:
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On July 8, 2014, Evotec announced an exclusive strategic collaboration with the Fraunhofer Institute for Molecular Biology and Applied Ecology IME in several disease areas through the combination of the relevant platforms of both organisations for internal and external drug discovery projects. This alliance expands Evotec\'s already powerful drug discovery platform with access to a broad range of complementary and highly innovative platforms and capabilities to progress own innovate projects and provides additional capabilities for customers and partners of Evotec and IME, respectively. The deal follows the joint decision of Evotec, Fraunhofer-Gesellschaft and the City of Hamburg to integrate the European ScreeningPort GmbH into the IME thereby forming the first Fraunhofer life science institution in the City of Hamburg. European ScreeningPort was founded in 2008 as a public private partnership. Founding shareholders include the Free and Hanseatic City of Hamburg and Evotec AG. The mission of the European ScreeningPort was to bridge the gap between basic academic research and the life sciences industry in the field of drug discovery and development. With state-of-the-art infrastructure at the VolksparkLabs in Hamburg, established processes and innovative technologies, ESP was able to position itself as a world-leading contract research organization for small-molecule screening, particularly for targets identified by academic partners.
Financial terms:
Latest news:
